BMS exec celebrates winning nod for 6 drugs in Korea in 2 years
Unlike many other global pharmaceutical giants choosing to divest and spin-off units, Bristol Myers Squibb (BMS) is aggressively expanding its pipeline through open innovation and strategic acquisitions. As a leading biopharma company, BMS is enhancing its …